CatalystFDA/Bio

DEFINIUM THERAPEUTICS, INC. (DFTX) DISCUSSES TOPLINE RESULTS FROM PANORAMA PHASE 3 STUDY OF DT120 ODT IN GENERALIZED ANXIETY DISORDER - SLIDESHOW - SEEKINGALPHA

Phase 3 topline results for DT120 ODT in generalized anxiety disorder drive biotech catalyst relevance.

What changed

Phase 3 topline results for DT120 ODT in generalized anxiety disorder drive biotech catalyst relevance.

Why it matters

Phase 3 topline results for DT120 ODT in generalized anxiety disorder drive biotech catalyst relevance. — impact context not separately stored; see What changed.

Sources

seekingalpha